Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

227.95 -2.29 (-0.99%)
Streaming Delayed Price Updated: 12:09 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
90 91 Next >
News headline image
AbbVie Options Trading: A Deep Dive into Market Sentiment ↗
 
Via Benzinga
News headline image
3 Cheap Stocks to Buy With Your Tax Refund Check ↗
Via The Motley Fool
News headline image
2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗
Via The Motley Fool
News headline image
13 Analysts Have This To Say About AbbVie ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About AbbVie? ↗
 
Via Benzinga
News headline image
Is AbbVie Stock a Buy Now? ↗
Via The Motley Fool
News headline image
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race ↗
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market. 
Via Benzinga
News headline image
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
News headline image
These Vanguard ETFs Show Where the Smart Money Is Moving Now ↗
Via The Motley Fool
Topics ETFs
News headline image
4 Sectors That Thrive When Inflation Runs Hot
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
Via MarketBeat
Topics Economy World Trade
News headline image
3 Reasons ABBV is Risky and 1 Stock to Buy Instead
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%. 
Via StockStory
Topics Stocks
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗
Via The Motley Fool
News headline image
2 High-Yield Dividend ETFs to Buy to Generate Passive Income ↗
With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer 
Via MarketBeat
Topics Death
News headline image
Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
News headline image
2 Magnificent Dividend Growth Stocks to Load Up On Right Now ↗
Via The Motley Fool
News headline image
4 Stocks and 1 Exchange-Traded Fund (ETF) I Can't Stop Buying ↗
Five great investments for any portfolio. 
Via The Motley Fool
News headline image
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
News headline image
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich ↗
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
News headline image
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? ↗
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers. 
Via Benzinga
News headline image
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
From Xilio Therapeutics, Inc.; AbbVie Inc.
Via GlobeNewswire
News headline image
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
News headline image
Healthcare And Biotech Playbook As Disruption Gathers Force ↗
The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year 
Via MarketBeat
News headline image
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. 
Via StockStory
News headline image
3 Fabulous Dividend Stocks to Buy in February ↗
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
90 91 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.